Table 5.
Multivariate Cox proportional hazard analyses for switched subsequent drug discontinuation
| Overall discontinuation | Discontinuation due to inadequate efficacy | |||
|---|---|---|---|---|
| Covariates | HR (95% CI) | p-Value | HR (95% CI) | p-Value |
| Female | 1.94 (1.01–3.62) | 0.046 | 2.58 (1.17–5.70) | 0.019 |
| Obese (BMI ≥ 25 kg/m2) | 1.35 (0.74–2.46) | 0.32 | 1.66 (0.76–3.52) | 0.21 |
| PsA versus PsO | 1.26 (0.68–2.33) | 0.47 | 1.11 (0.52–2.36) | 0.78 |
| GPP versus PsO | 0.79 (0.26–2.40) | 0.69 | 0.24 (0.04–1.35) | 0.11 |
| IL-12/23i versus TNFi | 0.56 (0.27–1.18) | 0.56 | 0.56 (0.23–1.40) | 0.22 |
| IL-17i versus TNFi | 0.59 (0.29–1.20) | 0.15 | 0.37 (0.15–0.93) | 0.034 |
| IL-23i versus TNFi | 0.93 (0.33–2.59) | 0.88 | 0.67 (0.21–2.20) | 0.51 |
Bold letters indicate a p-value of less than 0.05
HR hazard ratio, CI confidence interval, BMI body mass index, PsA psoriatic arthritis, PsO plaque psoriasis, GPP generalized pustular psoriasis, IL-12/23i IL-12/23 inhibitor, TNFi TNF inhibitor, IL-17i IL-17 inhibitor, IL-23i IL-23 inhibitor